I brought up this issue many many moons ago and it was viewed that there are enough indications to go around - over 100 - so there are plenty of opportunities for both organizations to pursue.
Acadia hadn’t even moved Trof in Fragile x yet - with the time and cost associated to bring a single indication to market I think we’re not at risk of running out of opportunities.
My question always was what if Acadia go after the “big ones” ie Autism and other - I also asked Jon with no response.
ANAVEX MEETS ENDPOINTS PHASE2 RETT, page-151
-
- There are more pages in this discussion • 16 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$13.38 |
Change
-0.275(2.01%) |
Mkt cap ! $1.719B | |||
| Open | High | Low | Value | Volume |
| $13.68 | $13.68 | $13.35 | $777.0K | 57.62K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 1336 | $13.37 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.38 | 85 | 5 |
View Market Depth
| Last trade - 11.19am 18/09/2024 (20 minute delay) ? |
| NEU (ASX) Chart |